Category Archives: Stell Cell Research

Infiniti’s Market Monitoring Solution Helped a Cell Therapy Market Client Transform Next-Gen Therapy Supply Chains Into Patient Connected Value Chains…

LONDON--(BUSINESS WIRE)--Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on market monitoring solution. This success story highlights how the experts at Infiniti Research helped a cell therapy market client secure patient access for cell and gene therapies, transform next-gen therapy supply chains into patient connected value chains, and maintain an efficient treatment network.

Over the past few years, the cell therapy market has gained immense popularity globally owing to the advent of techniques like stem cell therapy, CAR-T cell therapy, and cord blood cell therapy. In addition, the cell therapy market is likely to benefit from the introduction of new cell types, offering companies huge business opportunities to reinforce their position in the global market. However, increasing enforcement of regulations and disruptive technologies are increasing challenges for companies operating in the cell therapy market. In order to address these pressing concerns, companies in the cell therapy market are need to take strategic approaches and tackle challenges coming their way.

We combine our deep industry knowledge and specialized solutions to deliver actionable insights that can lead to greater patient engagement and higher-quality care. Request a free proposal.

The Business Challenge:

A cell therapy market client, based out of Sweden, faced challenges in securing patient access and establishing appropriate reimbursement mechanisms. Also, the client focused on traditional supply chain management techniques. However, traditional supply chain management techniques did not help them create patient value in emerging therapy value chains. In addition, preparing sites to initiate therapy and managing site training and ongoing certification were challenging for the client. The client, therefore, wanted to take initiatives to address these rising challenges. They approached the experts at Infiniti Research to leverage their expertise in offering market monitoring solution.

We have executed around 30+ cell therapy projects by leveraging our end-to-end capabilities and global footprint across the value chain. Contact us today.

The Solution Offered:

To help the client tackle the above-mentioned challenges, the experts at Infiniti Research used a combination of technology assessment, market potential, marketing strategy, and market forecast study. The engagement also involved conducting secondary research of the cell therapy market and validating gathered data.

Infinitis market monitoring solution helped the client to:

Want to gather detailed insights into this engagement? Request more info and our experts will get in touch with you with relevant insights.

About Infiniti Research

Established in 2003, Infiniti Research, is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies. To know more, visit:

Infiniti's Market Monitoring Solution Helped a Cell Therapy Market Client Transform Next-Gen Therapy Supply Chains Into Patient Connected Value Chains...

Are stem cells really the key to making humans live longer? –

To some longevity acolytes, stem cells promise the secret to eternal youth. For a hefty fee, you can pay a startup to extract your own stem cells and cryogenically freeze them, in the hope that they can one day be used in a treatment to help extend your life.

Other firms let you bank stem cells from your babys umbilical cord and placenta after childbirth, if youre convinced the high cost represents an insurance policy against future illness. Or you can follow the example of Sandra Bullock and Cate Blanchett and opt for an anti-ageing cream made with stem cells derived from the severed foreskins of newborn babies in South Korea.

Stem cells are the parent cells which give rise to other cells in our bodies. Since scientists first isolated human embryonic stem cells in a lab and grew them over 20 years ago, they have been mooted as a source of great hope for regenerative medical treatments, including for age-related degenerative conditions such as Parkinsons, Alzheimers, heart disease and stroke.

But apart from a few small-scale examples, the only stem cell-based medical treatment practised in clinics uses haematopoietic stem cells found in the blood and bone marrow which only produce blood cells for transplants in blood cancer patients. These cells are taken from a patients sibling or an unrelated donor, before being infused into a patients blood, or theyre taken from a patients own blood before being reinfused. The procedure has been used to treat blood malignancies for almost half a century, and recently multiple sclerosis too. So how likely is it that the predictions about stem cells' longevity-enhancing powers will become a reality?

In September 2019, Google banned ads for unproven or experimental medical techniques such as most stem cell therapy, citing a rise in bad actors attempting to take advantage of individuals by offering untested, deceptive treatments [that can often] lead to dangerous health outcomes. The decision was welcomed by the International Society for Stem Cell Research, which emphasised that most stem cell interventions remain experimental. Selling treatments before well-regulated clinical trials have been done, the body said, [threatens public] confidence in biomedical research and undermines the development of legitimate new therapies.

Its easy to see how less scrupulous companies can exploit the allure of stem cells, which seem to occupy a place in our collective consciousness as a kind of magical elixir. High hopes for stem cell-based therapies have grown since 2006, when the Japanese biologist Shinya Yamanaka created a new technology to reprogram adult cells, such as skin cells, into a similar state to embryonic stem cells, which are pluripotent, meaning they can develop into any tissue in the body. The Nobel prize-winning breakthrough was hailed as a major step in the study of stem cells without the need for controversial embryo research, and towards the use of these human induced pluripotent stem cells to regenerate damaged or diseased organs or effectively grow new spare parts which could treat the life-limiting and life-shortening illnesses associated with ageing.

Gerontologist Aubrey de Grey, whose Strategies for Engineered Negligible Senescence (SENS) research foundation aims to eliminate ageing-related diseases, thinks the chances well soon have stem cell based therapies are high. For anything that's in clinical trials, you're talking about maybe five years before it's available to the general public, he says, citing stem cell treatments for Parkinsons disease, currently being tested in phase two clinical trials, as one of the developments he thinks is likely to come soonest.

However, given that these trials involve a relatively small number of participants and most clinical trials ultimately fail, his predictions might be overly optimistic. Often described as a maverick, De Grey believes that humans can live forever and there is a 50 per cent chance medical advances of which stem cell therapies will play an important part will make this a reality within the next 17 years. Though living forever, he says, is not the ultimate goal but a rather large side effect of medicine which will successfully prevent or repair the damage that comes with ageing.

For New Jersey-based Robert Hariri, who co-founded Human Longevity Inc, which set its sights more modestly on making 100 the new 60, stem cells derived from placentas present especially exciting opportunities. A biomedical scientist, surgeon and entrepreneur, Hariri says his current venture Celularity which is focused on engineering placental cells, including stem cells, to create drugs for cancer and other conditions is not as concerned about the actual age number, but about preserving human performance as we age and treating the degenerative diseases that rob us of our quality of life.

Many of those working in the field, however, remain cautious in their optimism. Researchers have highlighted the potential risks of giving pluripotent cells to patients, whether they are induced or embryonic, as these cells can develop cancer-causing mutations as they grow.

Davide Danovi, a scientist at Kings College Londons Centre for Stem Cells & Regenerative Medicine, says the path to stem cell-based therapy is very long and full of hurdles. The supply chain involves challenges, he says. On the one hand, allogeneic treatments those with stem cells derived from one individual and expanded into big batches to create cells to treat many individuals have the advantage of being similar to the traditional pharmaceutical business models. The product is clear, its something that comes in a vial and can be scaled up and mass produced, Danovi says. But this treatment can present a greater risk of rejection from the patient, as opposed to the more bespoke autologous option which is more expensive and time-consuming as it involves extracting a patients own stem cells before reprogramming them.

Danovi is most excited by the potential of stem cells to treat age-related macular degeneration. In 2017 Japanese scientist Masayo Takahash led a team that administered transplants of artificially grown retinal cells created from induced pluripotent stem cells taken from donors to five patients with the eye condition, which can cause blindness, and theyre reported to be doing well. The eye, he says seems to be a place where immunity plays less of a role relative to other issues, so you can host cells which come from another individual with fewer problems [of rejection]. But, with other organs such as the liver, he says there are major conceptual problems with creating enough tissue. Its like the clean meat burger - you're talking about a production that is, in many cases, not easy to reach with the current technology.

Hariri believes placentas will solve some of the production challenges crucially, theyre an abundant commodity, with the vast majority thrown out after childbirth. His interest was sparked 20 years ago when his oldest daughter was in the womb: When I saw her first ultrasound in the first trimester, the placenta had already developed into a relatively sizable organ, even though she was just a peanut-sized embryo. Id been taught that the placenta was nothing more than an interface, but [if that was the case], you would expect that it would grow at the same rate as the embryo. His curiosity piqued, he began to see the placenta not as an interface but as a biological factory, where stem cells could be expanded and differentiated to participate in the development of that foetus. That intrigued me and I started to collect placentas and just, you know, basically disassemble them.

Placentas have numerous benefits, he says they dont carry the same ethical controversy as embryonic stem cells, for one thing. Scientists working on embryonic stem cells have to destroy an early embryo, and that option yields them a dozen cells, which have to be culture-expanded in the laboratory into billions of cells. In contrast, the placenta houses, billions and hundreds of billions of cells, which can be expanded as well, but you're starting out with a dramatically larger starting material.

Increasingly, scientists in the anti-ageing sphere are focusing on an approach that seems like the opposite of planting fresh stem cells into our bodies. Experts such as Ilaria Bellantuono at Sheffield Universitys Healthy Lifespan Institute are working towards creating senolytics medication that could kill off our senescent cells, the zombie cells that accumulate in tissues as we age and cause chronic inflammation. I think stem cells are very good for specific disease, where the environment is still young, Bellantuono says, but the data in animal models tells us that senolytics are actually able to delay the onset and reduce the severity of multiple diseases at the same time for example, there is evidence for osteoarthritis, osteoporosis, cardiovascular disease, Alzheimer's, Parkinson's, and diabetes. She explains that while human trials are still in their early stages, senolytics are likely to be more cost-effective than stem cell therapy and the status quo of older patients taking multiple pills for multiple diseases, which can interact with each other. Besides, she adds, they may actually work in tandem with stem-cell based therapies in the future, with senolytics creating a more hospitable environment in tissues to allow stem cells to do their work.

And as for the so-called penis facial? Its far from the only ultra-expensive stem cell skincare making bold anti-ageing claims but youre probably better off saving your money, as you are with the experimental medical treatments on offer. Stem cells are definitely exciting but theyre not the key to eternal youth. At least, not yet.

Robert Harari will be one of the speakers at WIRED Health in London on March 25, 2020. For more details, and to book your ticket, click here

Why do modern tomatoes taste so bad?

How Tesla became the world's most overvalued car company

Marvel at the incredible real-life Iron Man

How Slack ruined work

Follow WIRED on Twitter, Instagram, Facebook and LinkedIn

Get The Email from WIRED, your no-nonsense briefing on all the biggest stories in technology, business and science. In your inbox every weekday at 12pm sharp.

by entering your email address, you agree to our privacy policy

Thank You. You have successfully subscribed to our newsletter. You will hear from us shortly.

Sorry, you have entered an invalid email. Please refresh and try again.

Read the original post:
Are stem cells really the key to making humans live longer? -

Cancer Stem Cell Market Projected to Garner a Revenue of $ 1,722.7 million at a CAGR of 10.3% by 2026 – Yahoo Finance

North America Cancer Stem Cell Market will dominate the global market during the projected period, owing to the rising number of cancer cases, and increasing treatments. Asia-Pacific Cancer Stem Cells Market is anticipated to grow up to $367.7 Million till 2026.

New York, USA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- The globalcancer stem cell market is estimated to reach $ 1,722.7 million by 2026 from $786.3 million in 2018 at a CAGR of 10.3% during the forecast period, according to a report published by Research Dive. The report provides a definition of the market, segment analysis, recent developments, its primary characteristics and differentiators, and sheds light on the various aspects of the competition the market has been witnessing. The report also includes an overview of the market size, different segments of the market, scope, trends and opportunities in the market.

Insights Study of Report

Key segments of the market

The report offers an overview of the global cancer stem cell market with a precise outlook of its primary segments. The report segments the market by cancer form, application, and region.

Based on cancer form, the report divides the market into lungs, livers, breast, pancreas, brain, bladder, colon, and blood. Based on application, the report divides the market into targeted cancerous stem cells, stem cell-based cancer therapy, and others. By geography, the report bifurcates the market into North America, Europe, Asia-pacific, and LAMEA.

Major Growth Drivers

Rising prevalence of cancer all over the globe is giving significant boost to the growth of cancer stem cells market. Poor food habits, rising prevalence of deskbound work and increase in alcohol consumption among populace are the frequent reasons for the increasing number of cancer patients in the world. According to the Cancer Research UK, there were around 17 million cancer cases registered in 2018, out of which 9.6 million were fatal cases. There are many key factors that may affect the success rate of chemotherapy and a person's survival rate such as age, overall health and cancer stage.

Report Study Inquiry


Inequality issues coupled with expensive cell therapy treatments will pose a severe threat to the Cancer Stem Cells Market growth. On the other hand, according to CBC Canada, stem cell treatment for each person costs around $5,000 to $8,000. Therefore, due to economic inequalities among the population, the people from middle class and lower middle class sectors are unable to adopt this technology. Moreover, inequalities in diagnosis and treatments through stem cell treatment is significantly hampering the growth of cancer stem cells market.

Growth estimations by Segments

By cancer form, breast cancer market generated a revenue of $133.7 million in 2018, and is further projected to reach upto $295.0 million by the year of 2026. Differences in lifestyle, genetic influences of hormones and consumption of alcohol are the common reason for rising cases of cancer patients around the world.

By application segment, stem cell based cancer therapy generated a revenue of $440.3 million in 2018, and is projected to reach upto $896.9 million by the end of 2026.

North America to dominate the market

According to analyst expert, North America will dominate the global market during the projected period, owing to the rising number of cancer cases, and increasing treatments. North America market was $365.6 million in 2018, and is further projected to generate revenue of $783.8 million by 2026. In this region, U.S. and Canada are mainly heading the cancer stem cell market. The North America market is expected to grow over the forecast period due to various factors. One of the main factors is the increasing doctors involvement in the promotion of stem cell interventions, which are ethical, legal, and regulatory. For instance, the Canadian physicians are getting involved in promoting and providing unproven & unapproved stem cell interventions.

Top market players in Cancer Stem Cell Industry

The report highlights the major market players. They include AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.

Story continues

Mr. Abhishek Paliwal

Research Dive30 Wall St. 8th Floor, New York,NY 10005 (P).

+1 917 444-1262+1 917 444-1263+ 1-888-961-4454

Read the original:
Cancer Stem Cell Market Projected to Garner a Revenue of $ 1,722.7 million at a CAGR of 10.3% by 2026 - Yahoo Finance

Total Therapy Approach May Improve Transplant Outcomes in Patients With Myeloma – Hematology Advisor

Novel therapies developed in the past several decades may have improved long-term survival for patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT), with more patients in the past several years having what approaches a normal life expectancy, according to research published in Blood Advances. Outcomes differ, however, depending on patient age, disease risk group, and cytogenetic characteristics.

Previously published data suggest that patients with MM had the best survival outcomes in the period between 2002 and 2004, with a 5-year relative survival of 34.7%. However, inevitable disease relapses have been found to occur at increasingly short intervals in this patient population.

ASCT is a further mainstay of MM management, and there are limited data regarding outcomes among patients who undergo the total therapy approach, which involves induction therapy, ASCT, maintenance, and novel therapies as they become available for use. For this study, researchers evaluated outcomes among patients with MM who underwent total therapy and for whom long-term data were available.

Overall, 4329 patients were included in the analysis, with a median age of 58.9 years (range, 17.4-84.9) and 72.1% of patients being younger than 65 years; 2646 patients (61.1%) were male, 3723 (86%) were Caucasian, and 1861 (43%) were enrolled in a total therapy clinical trial. Patients were also categorized by the year in which they underwent ASCT: 1997 or earlier (661 patients), 1998 to 2003 (1002 patients), 2004 to 2008 (1294 patients), 2009 to 2013 (837 patients), and 2014 or later (535 patients).

The overall median follow-up was 10.5 years (range, 0.01-26.4), with patients who received ASCT in 1997 or earlier having the longest median follow-up (21.5 years) and those who received ASCT in 2014 or later having the shortest (2.5 years).

Overall survival improved over the evaluated period, with patients who received ASCT in 2014 or later having a hazard ratio for mortality of 0.35 compared with patients in the 1997 or earlier group (early mortality, 32.3% vs 36.4%). Other independent predictors of early mortality across the patient sample included age of 65 years or greater (37.2% vs 27.6% in patients younger than 65 years), high Gene Expressing Profile 70 risk status (61.4% vs 17.5% for patients with low risk), and presence of a chromosomal abnormality (41.7% vs 22.8% for patients with no abnormalities).

Being enrolled in a total therapy clinical trial was also associated with better early mortality (20.9% vs 37.9% for patients not on a total therapy protocol).

Going forward, it is clear that continued efforts to control and eradicate residual disease will be important strategies to increase the likelihood of achieving MM cure, the researchers wrote.


1. Nishimura KK, Barlogie B, van Rhee F, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4:422-431. doi:10.1182/bloodadvances.2019000524

Go here to read the rest:
Total Therapy Approach May Improve Transplant Outcomes in Patients With Myeloma - Hematology Advisor

Canine Stem Cell Therapy Market 2025: Research By Top Manufacturers with Market Size,Market Growth, Competitive Regions with Opportunities in Industry…

Global Canine Stem Cell Therapy Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Canine Stem Cell Therapy industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Request For Discount On This Report @

For competitor segment, the report includes global key players of Canine Stem Cell Therapy as well as some small players.

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:


End User:


Request Sample Report @

Important Key questions answered in Canine Stem Cell Therapy market report:

What will the market growth rate, Overview, and Analysis by Type of Canine Stem Cell Therapy in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Canine Stem Cell Therapy market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Canine Stem Cell Therapy market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

Buy This Report @

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Canine Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Canine Stem Cell Therapy , with price, sales, revenue and global market share of Canine Stem Cell Therapy in 2019 and 2015.

Chapter 3, the Canine Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Canine Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Canine Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Canine Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

See the original post:
Canine Stem Cell Therapy Market 2025: Research By Top Manufacturers with Market Size,Market Growth, Competitive Regions with Opportunities in Industry...

The global transplant diagnostics market is expected to grow at a CAGR of over 6% during the forecast period 2019-2025 – Yahoo Finance

NEW YORK, Feb. 14, 2020 /PRNewswire/ --

The global transplant diagnostics market is expected to grow at a CAGR of over 6% during the forecast period 20192025.

Read the full report:

The following factors are likely to contribute to the growth of the transplant diagnostics market during the forecast period: Growing Number of Transplantations & Prevalence of Chronic Diseases Increasing Shift from Serological to Molecular Diagnostic Testing in Transplant Patients Emergence of cfDNA in Transplant Diagnostics Increasing Focus on Identifying New Biomarkers for Minimizing Transplantation Rejection

The global transplant diagnostics market is growing at a steady rate, which is expected to continue during the forecast period. The high demand for molecular diagnostic tests and the availability of technologically advanced devices with favorable patient demographics are mainly contributing to the high demand for transplant diagnostics devices. Ongoing technological advancements and innovations witnessed in the development of new genomic, transcriptomic, and proteomic biomarkers, especially in the molecular segment, can provide personalized management for transplantation and can detect rejection episodes and infections early, thereby improving the patient outcomes and success rate.

The study considers the present scenario of the global transplant diagnostics market and its market dynamics for the period 2019?2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Transplant Diagnostics Market: Segmentation

This research report includes detailed market segmentation by product, application, technology, transplantation type, end-user, and geography. The increasing usage of a wide array of reagents and test kits to perform transplant diagnostics tests is a significant factor affecting the growth of the reagents & consumables product segment. The segment is growing at a faster rate than the instruments & software product segment due to their recurring purchase by end-users for performing molecular and non-molecular transplant tests. The growth in technological advancements such as NGS and PCR-based molecular testing techniques is another factor driving the adoption of molecular transplant assays, test kits, and reagents.

The instruments and software segment is growing due to the rise in organ and tissue transplantations and the adoption of advanced techniques. The segment is growing at a relatively slow pace than the consumables & test kits segment as it is capital intensive, and purchasing decisions for these equipment depend on financial resources and budget allocations. However, the recent trends in automation and integration of several medical platforms have led to the introduction of innovative transplant diagnostic analyzers, thereby driving the growth of the segment.

The research application segment is likely to witness faster growth than the clinical application segment as the number of research activities and clinical trials related to transplantation, especially stem cells, is increasing worldwide. The increase in the number of clinical trials and ongoing research activities to improve clinical outcomes is encouraging end-users to effectively screen donors and recipients, perform compatibility assessments and diagnose complications such as organ rejection and infections using molecular and non-molecular tests.The diagnostics applications segment is growing at a healthy rate and is expected to grow during the forecast period. Transplantation is the treatment of choice for several patients with end-stage organ failure diseases. Significant signs of progress have been achieved both in short-term outcomes and long-term graft survival due to the increasing availability of molecular and serological-based tests to monitor transplant patients. Hence, technological improvements have further increased the application of the segment.

The growing number of solid organ and stem cell replacement, advances in organ transplantation, increase in funding and research grants, and improved public-private investments, and the shift from serological-based tests to gene-based HLA profiling are major factors contributing the growth of the segment. The growing adoption of molecular-based techniques in transplantations with the wide availability of PCR and sequence-based products is contributing to the growth of the segment.Advances in serology and cellular assays have broadened the scope of transplant immunology technologies. Non-molecular tests have also been contributing sizeable revenues to the global transplant diagnostics market. Their potential in antibody-based histocompatibility tests, especially for lymphocyte micro cytotoxicity testing, has been fueling the demand. Several vendors are offering non-molecular testing products, which is further contributing to the growth.

Solid-organ transplantation has become vital in treating patients suffering from terminal illnesses. Therefore, the global number of solid organ transplantations is increasing at a healthy rate despite interruptions in the organ donation supply mechanism. Incidences of end-stage organ failures are high among patients with chronic diseases, thereby increasing the need for solid organ transplantations. The growth in hematological cancer cases is a key factor for the increasing demand for stem cell therapy worldwide.

Standard reference laboratories conduct tests to identify donor receiver compatibility pre-transplantation. As the number of organs, cells, and tissue replacements is growing worldwide, the demand for laboratory testing is likely to rise at a steady rate. Government financial support for these laboratories is another major factor for the growth of the segment. Academic institutes & research laboratories end-users are growing at a healthy rate as these centers conduct research studies for evaluating the efficacy and safety of immunosuppressive therapies for organs, cell, and tissue replacements.Healthcare professionals in hospitals and transplant centers use various instruments, accessories, and software for conducting pre and post-transplantation diagnostics tests. The market is growing at a healthy rate due to the adoption of advanced instruments accessories and software for organs, cells, and tissue transplantations. The availability of skilled healthcare professionals to perform diagnostics tests also attracts more patients to hospitals and transplant centers. Also, favorable reimbursement for transplant diagnostics is another factor boosting the end-user segment.

Market Segmentation by Product Instruments & Software Consumables & Test KitsMarket Segmentation by End-user Standards Reference Laboratories Hospitals and Transplant Centers Research and Academic CentersMarket Segmentation by Transplant Type Solid Organs Soft TissuesMarket Segmentation by Technology Molecular Non-molecularMarket Segmentation by Application Diagnostic Research

Insights by Geography

The presence of a large pool of the patient population with terminal diseases and the high acceptance of advanced and innovative molecular procedures for transplant diagnostics have collectively supported the growth. France, the UK, Spain, Germany, and Italy are the major revenue contributors to the Europe market. The availability of highly sophisticated healthcare infrastructure and high awareness of advanced transplant procedures are contributing to the growth during the forecast period.The APAC region has the largest population density and the highest proportion of various chronic diseases. China is the major revenue contributor in APAC. The region is expected to witness significant growth due to advancements in healthcare infrastructure, the rise in healthcare expenditure, and favorable public and private initiatives.

Market Segmentation by Geography Europeo Spaino Franceo Germanyo UKo Italy North Americao Canadao US APACo Chinao Japano South Koreao Indiao Australia Latin Americao Brazilo Argentinao Mexico MEAo Saudi Arabiao Irano South Africao Israel

Insights by VendorsThe global transplant diagnostics market is moderately competitive and characterized by the presence of a few players offering these products. It is consolidated with a few players accounting for around 75% of the overall market in 2019. The market is witnessing rapid technological advancements, especially in the molecular diagnostics segment. Moreover, key players are witnessing increased competition from various regional and local players globally.

Key Vendors Thermo Fisher Scientific Hoffmann-La Roche bioMrieux Bio-Rad Laboratories QIAGEN Immucor

Other Vendors BAG Diagnostics CareDx ELITechGroup Genome Diagnostics Illumina NanoString Technologies Omixon Transplant Genomics Wakunaga Pharmaceutical

Key Market InsightsThe analysis of the transplant diagnostics market provides sizing and growth opportunities for the forecast period 20192024. Offers sizing and growth prospects of the transplant diagnostics market for the forecast period 20192024. Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market. Includes a detailed analysis of growth drivers, challenges, and investment opportunities. Delivers a complete overview of segments and the regional outlook of the transplant diagnostics market. Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain a competitive advantage.

Read the full report:

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

View original content:

SOURCE Reportlinker

Follow this link:
The global transplant diagnostics market is expected to grow at a CAGR of over 6% during the forecast period 2019-2025 - Yahoo Finance

Stem Cell Therapy Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 – Instant Tech News

Verified Market Research recently added a research report titled, Stem Cell Therapy Market Size and Forecast to 2026. The research report represents the potential growth opportunities that prevail within the global market. The report is analyzed on the idea of secondary research methodologies acquired from historic and forecast data. The Stem Cell Therapy market is expected to grow substantially and thrive in terms of volume and value during the forecast period. The report will provide an insight into the growth opportunities and restraints that construct the market. Readers can gain meaningful comprehension about the future of the market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Request a Sample of this report @

Top 10 Companies in the Stem Cell Therapy Market Research Report:

Osiris Therapeutics, Medipost Co., Anterogen Co., Pharmicell Co., HolostemTerapieAvanzateSrl, JCR Pharmaceuticals Co., Nuvasive, RTI Surgical, Allosource

Competitive Landscape

The insightful research report on the Stem Cell Therapy market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior. It helps the reader understand the strategies and collaborations that players are that specialize in combat competition within the market. The comprehensive report provides a big microscopic check out the market. The reader can identify the footprints of the manufacturers by knowing about the worldwide revenue of manufacturers, the worldwide price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Global Stem Cell Therapy Market: Drivers and Restraints

The report offers underlying drivers that compel the consumers to take a position within the products and services. The detailed information assists readers in understanding the requirements of consumer demands. The report provides drivers at the local and global levels to assist determine the economic process . This information will help readers decide potential strategies that can help them stay ahead in the competitive industry.

Restraints provided in this section of the report contrasts the drivers segment as it explains the factors that can hamper the growth of the Stem Cell Therapy market during the forecast period. Restraints play a pivotal role in the global and regional market as it bends the prospective opportunities in the market. Readers can weigh and asses the drivers and restraints before making any investments or strategies.

Global Stem Cell Therapy Market: Segment Analysis

The report includes major segments like product type and end-user that provide an array of components that determine the portfolio of the Stem Cell Therapy industry. Each type furnishes information regarding the sales value during the forecast period. The understanding of the segment directs the readers in recognizing the importance of things that shape the market growth.

Global Stem Cell Therapy Market: Regional Analysis

This section of the report provides detailed information about each region and how numerous factors of that particular region affect the growth of the Stem Cell Therapy market. The government policies, weather, politics, and other factors determine the longer term of the market differently in each region. The major regions covered in the report include North America, Europe, Asia Pacific, the Middle East, and Africa, and others.

Ask for Discount @

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Therapy Market Size, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis, Stem Cell Therapy Market Trends, Stem Cell Therapy Market

Here is the original post:
Stem Cell Therapy Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 - Instant Tech News

Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime – National Institutes of Health

News Release

Thursday, February 13, 2020

NIH-supported research of Hydractinia could provide clues to human reproductive conditions.

A little-known ocean-dwelling creature most commonly found growing on dead hermit crab shells may sound like an unlikely study subject for researchers, but this animal has a rare ability it can make eggs and sperm for the duration of its lifetime. This animal, called Hydractinia, does so because it produces germ cells, which are precursors to eggs and sperm, nonstop throughout its life. Studying this unique ability could provide insight into the development of human reproductive system and the formation of reproductive-based conditions and diseases in humans.

By sequencing and studying the genomes of simpler organisms that are easier to manipulate in the lab, we have been able to tease out important insights regarding the biology underlying germ cell fate determination knowledge that may ultimately help us better understand the processes underlying reproductive disorders in humans, Dr. Andy Baxevanis, director of the National Human Genome Research Institutes (NHGRI) Computational Genomics Unit and co-author of the paper. NHGRI is part of the National Institutes of Health.

In a study published in the journal Science, collaborators at NHGRI, the National University of Ireland, Galway, and the Whitney Laboratory for Marine Bioscience at the University of Florida, Augustine, reported that activation of the gene Tfap2 in adult stem cells in Hydractinia can turn those cells into germ cells in a cycle that can repeat endlessly.

In comparison, humans and most other mammals generate a specific number of germ cells only once in their lifetime. Therefore, for such species, eggs and sperm from the predetermined number of germ cells may be formed over a long period of time, but their amount is restricted. An international team of researchers have been studying Hydractinias genome to understand how it comes by this special reproductive ability.

Hydractinia lives in colonies and is closely related to jellyfish and corals. Although Hydractinia is dissimilar to humans physiologically, its genome contains a surprisingly large number of genes that are like human disease genes, making it a useful animal model for studying questions related to human biology and health.

Hydractinia colonies possess feeding polyps and sexual polyps as a part of their anatomy. The specialized sexual polyps produce eggs and sperm, making them functionally similar to gonads in species like humans.

During human embryonic development, a small pool of germ cells that will eventually become gametes is set aside, and all sperm or eggs that humans produce during their lives are the descendants of those original few germ cells. Loss of these germ cells for any reason results in sterility, as humans do not have the ability to replenish their original pool of germ cells.

In a separate study, Dr. Baxevanis at NHGRI and Dr. Christine Schnitzler at the Whitney Lab have completed the first-ever sequencing of the Hydractinia genome. In this study, researchers used this information to scrutinize the organisms genome for clues as to why there are such marked differences in reproductive capacity between one of our most distant animal relatives and ourselves.

Having this kind of high-quality, whole-genome sequence data in hand allowed us to quickly narrow down the search for the specific gene or genes that tell Hydractinias stem cells to become germ cells, said Dr. Baxevanis.

The researchers compared the behavior of genes in the feeding and sexual structures of Hydractinia. They found that the Tfap2 gene was much more active in the sexual polyps than in the feeding polyps in both males and females. This was a clue that the gene might be important in generating germ cells.

The scientists next confirmed that Tfap2 was indeed the switch that controls the process of perpetual germ cell production. The researchers used the CRISPR-Cas9 gene-editing technique to remove Tfap2 from Hydractinia and measured the resulting effects on germ cell production. They found that removing Tfap2 from Hydractinia stops germ cells from forming, bolstering the theory that Tfap2 controls the process.

The researchers also wanted to know if Tfap2 was influencing specific cells to turn into germ cells. Their analysis revealed that Tfap2 only causes adult stem cells in Hydractinia to turn into germ cells.

Interestingly, the Tfap2 gene also regulates germ cell production in humans, in addition to its involvement in myriad other processes. However, in humans, the germ cells are separated from non-germ cells early in development. Still, despite the vast evolutionary distance between Hydractinia and humans, both share a key gene that changes stem cells into germ cells.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at:

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIHTurning Discovery Into Health


Read this article:
Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime - National Institutes of Health

Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord…

The new research report providing thorough analysis on GlobalCord Blood Stem Cell Marketwhich peaks the market size, inclusive market dynamics and high technology updates of Cord Blood Stem Cell market with respect to industry opportunities, threats, challenges, constraints, cost structure and current trend in the market. The Cord Blood Stem Cell industry report is a thorough study of the market where the customer can gain key intuition into the market such as the performance of the market in terms of its market (size and value) for its various segmentations such as storage service, application, and region. This research assists to understand the competitive outlook of Cord Blood Stem Cell market by key players Cord Blood Registry Systems Inc, Viacord Inc., China Cord Blood Corporation., Cord Blood America Inc, Cryo-Cell International Inc, Cryo-Save AG., Cordlife Group Ltd., Vita 34 AG., Lifecell International Pvt. Ltd., Stemcyte Inc..

The research report consists of primary and secondary data which has been further epitomized through various charts, bar graphs, pie charts, tables and market figures. Additionally, detailed landscaping, Cord Blood Stem Cell economic strategy, marketing scheme, as well as SWOT analysis & Porte Five Forces Analysis of the market players have been provided in the Cord Blood Stem Cell report. It also includes the inventive trends, executing a rational pricing stats in the competitive Cord Blood Stem Cell market. The report also categorizes the market in terms of volume and revenue [Million USD].

To Obtain All-Inclusive Information On Forecast Analysis Of GlobalCord Blood Stem CellMarket, Download FREE SamplePDF Report Here

The Cord Blood Stem Cell market report covers revenue number, product details, and sales of the leading Cord Blood Stem Cell corporations. The international market for Cord Blood Stem Cell has been researched with every detail in the publication with increased prominence on various important factors such as opportunities, and self-controlled, growth drivers. Each of the factors that concern to creation of the Cord Blood Stem Cell market dynamics has been studied and analyzed in detail by the Cord Blood Stem Cell analysts, so as to offer the best and most assessing and comprehensive study to the buyers of Cord Blood Stem Cell report.

The snapshot or the directional summary that has been provided in the Cord Blood Stem Cell market intelligence study has been designed in such a way that it will give a quick overview of the market for receiving information on the go. This could assist Cord Blood Stem Cell readers with hands-on data required for decision making during their progress journey in the Cord Blood Stem Cell market.

Global Cord Blood Stem Cell Market Research Report 2020-2029 Includes

Download Free Sample PDF Copy of This Research Report Now!

Geographically, this Cord Blood Stem Cell report is divided into different key regions, with production, Cord Blood Stem Cell utilization, income (million USD), and market share and the rate of growth in these regions, from 2020 to 2029 (forecast), covering Cord Blood Stem Cell market in North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain, etc), South America (Brazil, Argentina, etc), Middle East & Africa Cord Blood Stem Cell market (Saudi Arabia, South Africa, etc) and its Share (%) and CAGR for the predicted period 2020 to 2029.

The Key Points of this Cord Blood Stem Cell Market Report are:

1) To survey and forecast the market size share of Cord Blood Stem Cell, in terms of value and volume.

2) Provide detailed information concerning the Cord Blood Stem Cell major factors (opportunities, drivers, restraints, and industry-specific challenges) influencing the growth of Cord Blood Stem Cell market.

3) To study the future outlook and prospects for the Cord Blood Stem Cell market with Marketing Price (Price and Margin, Factors of Price Change, Manufacturers Gross Margin Analysis)

4) To analyze the global key regions Cord Blood Stem Cell market potential and advantage, opportunity and challenge, restraints and risks.

5) Detail Profile of the dominant players and Cord Blood Stem Cell comprehensively analyses their market status in terms of ranking and core capability along with in-depth the Cord Blood Stem Cell competitive landscape for the market leaders.

6) Study competitive developments like partnerships and joint ventures, Cord Blood Stem Cell new product developments, expansions and research and development of Cord Blood Stem Cell market.

Inquire/Speak To Expert for Further Detailed Information About Cord Blood Stem Cell Report:

Note: The historical years of the report and the forecast period can be personalized upon request. [Post Your Research Requirements] In addition, the scope of the published report can be changed as needed, detailed geography or country-based information can be given as part of the customization process.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson (

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States


See the rest here:
Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord...

Flow Cytometry Market to be Worth Over $6.4 Billion by 2027 With CAGR of 8.2%| Top Key Players Like –

Meticulous Research leading global market research company published a research report titledFlow Cytometry Market by Product & Solution (Consumables, Instrument, Software, Service), Technology (Cell-based, Bead-based), Application (Cancer, Immunology, Hematology), and End-user (Pharmaceutical, Biotech, Academia) Global Forecast to 2027.

According to this latest publication from Meticulous Research, the globalFlow Cytometry Market is expected to grow at a CAGR of 8.2% from 2019 to reach to $6.4 billion by 2027. The growth of the flow cytometry market is mainly attributed to the rising global incidence and prevalence of chronic diseases, increasing adoption of flow cytometry techniques in research and academia, and growing initiatives in the field of immunology and immuno-oncology researches. Moreover, the evolving pipeline for stem cell research and the adoption of recombinant DNA technology for antibody production offer significant growth opportunities for the players operating in this market. However, complexities related to reagents development is the key factor expected to hinder the adoption of flow cytometry products to a certain extent.

Access Free Complete Free Sample PDF Copy Here:

Key questions answered in the report-

Which are the high growth market segments in terms of product & services, technology, application, end-users, and region/countries?What was the historical market for flow cytometry across the globe?What are the market forecasts and estimates for the period 2019-2027?What are the major drivers, restraints, opportunities, and challenges in the overall flow cytometry market?Who are the major players in the flow cytometry market?How is the competitive landscape and who are the market leaders in the overall flow cytometry market?What are the recent developments in the overall flow cytometry market?What are the different strategies adopted by the major players in the overall flow cytometry market?What are the geographical trends and high growth regions/ countries?

Have Any Query? Ask Our Experts Here:

The global flow cytometry market study presents historical market data in terms of values (2017 and 2018), estimated current data (2019), and forecasts for 2027- by product & solution (consumables, instrument, software, service), technology (cell-based, bead-based), application (cancer, immunology, hematology, industrial), end-user (pharmaceutical & biotech companies, research & academia, diagnostic laboratory) forecast to 2027. The study also evaluates industry competitors and analyzes the market at a regional and country level.

Based on technology,the cell-based technology segment held the largest share of the overall flow cytometry market in 2019. The large share of this segment is mainly attributed to the increasing utilization of this technology in research and development activities of novel therapeutic drugs and the advantage of analyzing characteristics and properties of targeted cells with ease. On the other hand, bead-based technology is expected to grow at a higher CAGR during the forecast period owing to the several procedural advantages offered by this technology.

Based on product and solution,the consumables and reagents segment accounted for the largest share of the overall flow cytometry market in 2019 and is expected to grow at the highest CAGR during the forecast period. The commercialization of high-quality application-specific reagents and assays by end-users is supporting the growth of this segment. Also, the continuous requirement of flow cytometry reagents by end-users further supports the growth of this segment.

Based on the end-user,the flow cytometry market is broadly segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, and research & academic institutes. During the forecast period, the diagnostic laboratory segment is expected to register the fastest growth in the flow cytometry market. Some of the major factors contributing to the fastest growth of this segment are rising prevalence of chronic and infectious diseases, growing awareness regarding various chronic diseases, rising willingness to get an accurate diagnosis, and a growing number of laboratories adopting flow cytometers as the advanced diagnostic technology.

Check complete table of contents with a list of table and figures:

Geographically, North America commanded the largest share of the global flow cytometry market in 2019, followed by Europe and Asia Pacific. The factors such as the availability of skilled professionals, higher awareness level, and the presence of supportive government reforms for the development of advanced technologies are accelerating the flow cytometry market in the North American region.

Key players:

The key players operating in the global flow cytometry market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMrieux S.A. (France), Cytonome/ST LLC (U.S.), Beckman Coulter, Inc. (U.S.), and Becton, Dickinson and Company (U.S.) among others.

Download Sample Report Now !!

Related Reports:

Infectious Disease Diagnostics Market by Product (Assays and Kits, Instruments, and Software and Services), Technology (Immunodiagnostics, NGS, PCR), Disease Type (Hepatitis, HIV, HPV, Tuberculosis), End User, and Geography Global Forecast to 2025

In Vitro Diagnostics Market | IVD Market By Product (Reagent, Instruments, Software, Service), Technique [Immunoassay, Clinical Chemistry (Lipids, Renal, Thyroid), PCR], Application (Hematology, Diabetes, Nephrology, Oncology), End User (Hospital, POC) Global Forecast to 2024

Contact Us:

Meticulous Research

Contact Sales- +1-646-781-8004

Connect with us on LinkedIn-

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at

See original here:
Flow Cytometry Market to be Worth Over $6.4 Billion by 2027 With CAGR of 8.2%| Top Key Players Like -